However, other investigations have reported lower sclerostin levels are associated with VC, and a meta-analysis has indicated sclerostin levels are not predominantly associated with all-cause and VC-related mortality risk in patients with CKD [186, 187]. Here, SOST is linked to chronic kidney disease.